Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks Trump's new tariff move may raise U.S. pharma costs, with analysts warning of ...

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

As an independent biotechnology company, Biogen (Cambridge, MA) has led innovation in treatment and outcomes assessment in MS for >25 years and continues to have an enduring commitment to elevate ...

But that doesn't mean long term investors can avoid big losses. For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Ivana Rubino works at Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States. Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...